At a glance
ClinicalIndex Comparison RecordPhase 3Completed· 35 enrolled
Drug / intervention
BFF +1 morecombination
Likely dose
Not stated in record
Structured eligibility isn't available for this trial yet — see the full criteria in the Eligibility tab below.
Standardized by ClinicalIndex from the ClinicalTrials.gov record · verify against the source.
A Randomized, Open-Label, Two Period Crossover, Chronic Dosing, 1-Week, Pilot Study to Assess the Efficacy and Safety of Budesonide and Formoterol Fumarate Inhalation Aerosol Administered With a Spacer Compared With Symbicort® Turbuhaler® in Subjects With Severe to Very Severe Chronic Obstructive Pulmonary Disease and Low Peak Inspiratory Flow
In Brief
A Phase 3 clinical trial evaluating BFF and Symbicort Turbuhaler for Chronic Obstructive Pulmonary Disease (COPD). Completed, enrolled 35 participants across 4 sites.
Detailed Summary
Study comparing the same drugs as a dual combination product (budesonide and formoterol) given via two different inhalers. To see which one results in the best effect on breathing.
Study Details
Study Typeinterventional
Allocation--
Masking--
Primary Purpose--
CountriesGermany
Collaborators--
Timeline
Phase 3CompletedFinished
2020202120222023202420252026
First PostedSep 2019
Enrollment StartSep 2019
Primary CompletionDec 2020
TodayJul 2026
First PostedSep 4, 2019
Enrollment StartSep 10, 2019
Primary CompletionDec 30, 2020
TodayJul 2, 2026
Enrollment to primary: 1.3 yearsPosted 6.8 years ago
Interventions
BFFcombination
Treatment with budesonide and formoterol furmate MDI (metered-dose inhaler)
Symbicort Turbuhalercombination
Treatment with budesonide and formoterol furmate DPI (dry-powder inhaler)